• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Atim-02. successful cancer-selective gene delivery following intravenous toca 511 delivery in patients with recurrent high grade glioma (hgg)
This study demonstrates successful gene transduction following IV delivery of Toca 511 and shows encouraging survival data. Updated safety and efficacy data will be presented.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Cloughesy, T., Walbert, T., Bota, D., Vogelbaum, M., Liau, L., Ostertag, D., Jolly, D., Gruber, H., Yang, L., Shorr, J., Kalkanis, S. Tags: ADULT CLINICAL TRIALS (IMMUNOLOGICAL) Source Type: research

Surg-38. direct evidence of plasticity within primary motor and sensory cortices via direct electrical stimulation in glioblastoma patients undergoing repeat awake craniotomy
In this study, we examine plasticity within primary sensory (S1) and motor (M1) cortices in glioblastoma patients undergoing repeat intra-operative direct electrical stimulation (DES) under awake conditions.METHODS:This retrospective analysis included five patients with glioblastoma in/near M1/S1 that underwent two awake surgeries, each with DES-based sensory and motor mapping. Inter-surgery interval was 216 ± 41 days. Plasticity was defined as a change in mapping result (gain, loss, or change of function) within M1/S1 at second operation or absence of typical mapping result without a change in the patient&rsqu...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Gibb, W., Kong, N. Tags: SURGICAL THERAPY Source Type: research

Ntox-08. safety of intra-arterial chemotherapy in the treatment of brain tumours
The treatment of brain tumors is greatly limited the delivery impediment caused by the blood-brain barrier and blood-tumor barrier. To circumvent this limitation, different approaches have been studied, including intra-arterial delivery. Because of a significant local increase in plasma-peak concentration, this strategy increases the local area under the curve, and translates into a 3 to 5.5 fold increase in intra-tumoral chemotherapy concentration. However, intra-arterial chemotherapy in the treatment of brain tumors has a notoriously bad name, thanks to prior trials led in past decades showing significant neurotoxicities...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Fortin, D., Caux, S., Gahide, G. Tags: NEUROTOXICITY OF THERAPY Source Type: research

Atim-18. phase i dose escalation study of d2c7-it administered intratumorally via convection-enhanced delivery (ced) for recurrent malignant glioma (mg)
CONCLUSION:Infusion of D2C7-IT via CED is safe thus far and encouraging efficacy results are observed. Enrollment is ongoing.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Desjardins, A., Randazzo, D., Chandramohan, V., Sampson, J., Peters, K., Vlahovic, G., Threatt, S., Herndon, J., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E., Friedman, A., Friedman, H., Bigner, D. Tags: ADULT CLINICAL TRIALS (IMMUNOLOGICAL) Source Type: research

P05.04 Morphine pretreatment improves the therapeutic efficacy of doxorubicin in an orthotopic model of human glioblastoma
Conclusions:The present findings show that molecules as morphine are able to interfere with molecules normally unable to cross the BBB. This mechanism could be used for new approaches in therapy of refractory CNS tumors as glioblastoma.
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Da Ros, M. Tags: P05 In vitro / in vivo models Source Type: research

P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma
The prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Koeppen, S., Hense, J. Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research

OS5.8 Intravascular lymphoma affecting the central nervous system: features and outcomes in a case series of the Primary CNS Lymphoma Collaborative Group (IPCG)
We present a retrospective case series of 65 adults with IVL from 14 cancer centers in 6 countries. IVL was restricted to the CNS in 29 cases, with a mean age of 60 years and 91% of patients having neurological deficits at the time of diagnosis. There was a mean diagnostic delay of 20 weeks after presentation of stroke-like symptoms or myelopathy. Ninety-three percent had a poor functional status with an Eastern Cooperative Oncology Group (ECOG) performance status ≥2. Serum LDH was elevated in 87% of patients with no correlation with treatment outcome. Frontline treatment with intravenous high-dose methotrexate-bas...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Zukas, A. M., Bennani, N., Chou, C., Johnston, P., ONeill, B., Nijland, M., Batchelor, T., Nayak, L., Mrugala, M., Schiff, D. Tags: OS5 Glioma: Clinical Source Type: research

Rt-08 * proton therapy (pt) large-volume re-irradiation for recurrent glioma: overall survival (os) and toxicity outcomes
CONCLUSION: Large-volume PT re-irradiation for recurrent glioma is safe and associated with promising OS outcomes, particularly in the setting of bevacizumab-refractory tumors.
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Desai, B., Rockne, R., Rademaker, A., Raizer, J., Paleologos, N., Merrell, R., Grimm, S., Azeem, S., Hartsell, W., Sweeney, P., Swanson, K., Gondi, V. Tags: RADIATION THERAPY (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research

Nc-01 * attentional and language functioning in adult patients with glioma: a voxel-based lesion-symptom mapping study
CONCLUSION: These findings identify some of the key anatomic structures involved in attentional and language functioning in adult patients with glioma using an innovative lesion analysis technique.
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Banerjee, P., Leu, K., Harris, R., Cloughesy, T., Bookheimer, S., Liau, L., Nghiemphu, P., Lai, A., Ellingson, B. Tags: NEURO-COGNITIVE AND FUNCTIONAL OUTCOMES Source Type: research

Cn-14 * retrospective analysis of ischemic cerebral strokes in patients diagnosed with a glioblastoma during the course of a bevacizumab treatment
Bevacizumab is an anti-vascular endothelial growth factor approved in the treatment of recurrent glioblastoma. It prolongs progression-free survival, improes radiologic response and contributes to reduce the dose of dexamethasone required to control peritumoral edema. Arterial and venous thromboembolic events represent significant toxicities related to the use of angiogenesis inhibitors. Various mechanisms could be implicated in bevacizumab-related strokes, as cardioembolic, lacunar stroke related to hypertension, deep venous thrombosis passing through a patent foramen ovale, pro-coagulant effect of the underlying glioblas...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Maurice, C., Mason, W. P. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research